Adial Pharmaceuticals Inc (NASDAQ: ADIL) announced advancements regarding its adenosine analog development platform, which is developed by Purnovate, Inc, which is a division of Adial Pharmaceuticals Inc itself. The company is a clinical-stage biopharmaceutical company that develops treatments for addictions.
Compounds are developed that are capable of influencing specifically targeted adenosine receptors. However, the compounds also are selective over the adenosine A1 receptor. Thus, a problem for many therapeutic indications can arise.
Selectivity has been achieved over the A1 receptor. The level of water solubility decreased. Concurrently, this has made it a challenge to make effective tissue distribution in the human body. Solubility more than 50 times more excellent than other known selective adenosine compounds of the same class has been demonstrated.
Dr. Robert D. Thompson, Adial’s Vice President, Chemistry, commented, “We are highly encouraged by the latest preclinical data related to our adenosine platform as a potential therapy for pain relief. Based on these data, we are proceeding with development of our compounds to determine if they may have broad implications as a replacement therapy for opioids or, when used in combination, as a way to support lower dose administration of opioids.
Tablets prove to have good oral bioavailability
Results of the test that have been performed have proved to be encouraging. Good oral bioavailability makes oral administration, like tablets, one of the most preferred options for dosing these compounds.
All tested compounds appear synergistic with morphine
Studies on animals were performed. Initial studies have brought to light that the compounds are pharmacologically active. Multiple compounds have demonstrated a meaningful in vivo reduction in pain (rodents). Meanwhile, compounds that have higher solubility levels appear synergistic with acetaminophen (Tylenol). All tested compounds appear synergistic with morphine. Purnovate, Inc. is working towards establishing relationships to test its compounds in asthma, cancer, and inflammation models.
Phase 3 clinical study to evaluate AD04 in patients with Alcohol Use Disorder (AUD)
As part of the 24-week ONWARD trial, under Phase 3 of the clinical study, efficacy, safety, and tolerability of AD04 in patients with Alcohol Use Disorder (AUD) will be evaluated. The trial will also study selected polymorphisms in the serotonin transporter and receptor genes. Before being enrolled in the ONWARD trial, patients are genetically screened. Only genetically positive patients are eligible to participate in the trial. The ONWARD trial is currently being conducted in 25 clinical sites in seven countries.